CPMD 8-K
Cannapharmarx, Inc. (CPMD)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
Current Report
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported):
(Exact name of registrant as specified in its charter)
|
(State or other jurisdiction of incorporation) |
(Commission File Number) | (IRS Employer ID No.) |
(Address of principal executive offices, including zip code)
(Registrant’s Telephone Number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act: None
Securities registered pursuant to Section 12(g) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| OTC Markets |
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b2 of the Securities Exchange Act of 1934 (§240.12b2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act.
| Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
Resignation of Chief Executive Officer
Pursuant to notice provided to the Company, Dean Medwid stepped down as the Chief Executive Officer (“CEO”) of CannaPharmaRX, Inc. (the “Company”) for personal reasons. There was no disagreement between Mr. Medwid and the Company on any matter related to the Company’s operations, policies or practices that led to Mr. Medwid’s resignation as CEO. The Company appreciates Mr. Medwid’s dedication and service to the Company. The Company is looking to work with Mr. Medwid on a smooth transition and minimal interruption to our operations.
The Company’s Board of Directors has started the process of finding a suitable replacement CEO for the Company. In the interim, the Board of Directors will work collectively with Company staff and employees to manage the day-to-day operations of the Company.
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
| CANNAPHARMARX, INC. | ||
| September 17, 2024 | By: | /s/ Rick Orman |
Name: Title: |
Rick Orman Chairman of the Board | |
| 3 |